NGeneBio (엔젠바이오)
Seoul, South Korea
NGeneBio (엔젠바이오) is a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx), which develops and provides next generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW). NGeneBio was as a joint venture between Genecurix and Korea Telecom. The company launched NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTestTM) with clinical analysis SW (NGeneAnalysisTM) in 2016. BRCA NGS panel for PARP inhibitor CDx test and solid tumor/hematologic cancer NGS panels will be launched, inclusive of clinical data analysis SW platform. The mission of the company is to provide clinically validated NGS based IVD/CDx products/services with convergence of innovative bioinformatics and SW development capacity for global market.
Only accessible to MedStartr community members.
Join nowCompany Info
- Founded
- 2015
- Website
- www.ngenebio.com/
Categories
Only accessible to MedStartr community members.
Join nowWhat do you think of NGeneBio (엔젠바이오)?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.
Only accessible to MedStartr community members.
Join now